share_log

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Benzinga ·  Sep 27, 2023 06:31

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment